These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 21071306)

  • 1. [Fatty liver and global cardiometabolic risk].
    Szollár L
    Orv Hetil; 2010 Nov; 151(47):1946-50. PubMed ID: 21071306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. From the metabolic syndrome to NAFLD or vice versa?
    Vanni E; Bugianesi E; Kotronen A; De Minicis S; Yki-Järvinen H; Svegliati-Baroni G
    Dig Liver Dis; 2010 May; 42(5):320-30. PubMed ID: 20207596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Patomechanisms of hepatic steatosis].
    Fülöp P; Paragh G
    Orv Hetil; 2010 Feb; 151(9):323-9. PubMed ID: 20159747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The central role of the non alcoholic fatty liver disease in metabolic syndrome.
    Hurjui DM; Niţă O; Graur LI; Mihalache L; Popescu DS; Graur M
    Rev Med Chir Soc Med Nat Iasi; 2012; 116(2):425-31. PubMed ID: 23077931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonalcoholic steatohepatitis and the metabolic syndrome.
    Jiang J; Torok N
    Metab Syndr Relat Disord; 2008 Mar; 6(1):1-7. PubMed ID: 18370830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cardiovascular link to nonalcoholic fatty liver disease: a critical analysis.
    Pacana T; Fuchs M
    Clin Liver Dis; 2012 Aug; 16(3):599-613. PubMed ID: 22824483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insulin resistance and metabolic syndrome in chronic liver diseases: old entities with new implications.
    Tsochatzis EA; Manolakopoulos S; Papatheodoridis GV; Archimandritis AJ
    Scand J Gastroenterol; 2009; 44(1):6-14. PubMed ID: 18661429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin resistance in nonalcoholic fatty liver disease.
    Bugianesi E; Moscatiello S; Ciaravella MF; Marchesini G
    Curr Pharm Des; 2010 Jun; 16(17):1941-51. PubMed ID: 20370677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Non invasive markers of non-alcoholic steatohepatitis].
    Raszeja-Wyszomirska J; Miezyńska-Kurtycz J; Marlicz W; Ławniczak M; Milkiewicz P
    Pol Merkur Lekarski; 2008 Aug; 25(146):166-70. PubMed ID: 18942340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular mechanisms of steatosis in nonalcoholic fatty liver disease.
    Pettinelli P; Obregón AM; Videla LA
    Nutr Hosp; 2011; 26(3):441-50. PubMed ID: 21892559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonalcoholic steatohepatitis and noncirrhotic hepatocellular carcinoma: fertile soil.
    Torres DM; Harrison SA
    Semin Liver Dis; 2012 Feb; 32(1):30-8. PubMed ID: 22418886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Non-alcoholic fatty liver disease and cardiovascular risk].
    Abel T; Fehér J
    Orv Hetil; 2008 Jul; 149(28):1299-305. PubMed ID: 18617457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathophysiology of nonalcoholic steatohepatitis.
    McCullough AJ
    J Clin Gastroenterol; 2006 Mar; 40 Suppl 1():S17-29. PubMed ID: 16540762
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonalcoholic fatty liver disease: from steatosis to cirrhosis.
    Farrell GC; Larter CZ
    Hepatology; 2006 Feb; 43(2 Suppl 1):S99-S112. PubMed ID: 16447287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Iron overload in nonalcoholic steatohepatitis.
    Fujita N; Takei Y
    Adv Clin Chem; 2011; 55():105-32. PubMed ID: 22126026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-alcoholic fatty liver disease and hepatitis C infection.
    Bondini S; Younossi ZM
    Minerva Gastroenterol Dietol; 2006 Jun; 52(2):135-43. PubMed ID: 16557185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular risk, lipidemic phenotype and steatosis. A comparative analysis of cirrhotic and non-cirrhotic liver disease due to varying etiology.
    Loria P; Marchesini G; Nascimbeni F; Ballestri S; Maurantonio M; Carubbi F; Ratziu V; Lonardo A
    Atherosclerosis; 2014 Jan; 232(1):99-109. PubMed ID: 24401223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of fructose-enriched diets in mechanisms of nonalcoholic fatty liver disease.
    Nomura K; Yamanouchi T
    J Nutr Biochem; 2012 Mar; 23(3):203-8. PubMed ID: 22129639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH.
    Traussnigg S; Kienbacher C; Halilbasic E; Rechling C; Kazemi-Shirazi L; Hofer H; Munda P; Trauner M
    Dig Dis; 2015; 33(4):598-607. PubMed ID: 26159280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Non-alcoholic fatty liver disease--new view].
    Raszeja-Wyszomirska J; Lawniczak M; Marlicz W; Miezyńska-Kurtycz J; Milkiewicz P
    Pol Merkur Lekarski; 2008 Jun; 24(144):568-71. PubMed ID: 18702346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.